Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing

被引:10
|
作者
Macaluso, Matthew [1 ]
Preskorn, Sheldon H. [1 ]
机构
[1] Univ Kansas, Sch Med, Wichita, KS 67214 USA
关键词
pharmacogenetic tests; drug metabolism; cytochrome P450 enzymes; antidepressants; antipsychotics; blood levels; GeneSight test; MAJOR DEPRESSIVE DISORDER;
D O I
10.1097/PRA.0000000000000345
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Several companies offer pharmacogenetic testing for psychiatry on the basis of the claim that the outcome of drug selection is better when guided by such testing than when such testing is not used. This column examines the results of the GeneSight Psychotropic Test which groups various antidepressants and antipsychotics into 3 bins: green (use as directed), yellow (use with caution), and red (use with increased caution and more frequent monitoring). The authors examined how frequently the same drugs appeared in these different bins in 19 patients. They found that of the 22 antidepressants evaluated, 2 were virtually always (>90%) in the green bin: desvenlafaxine and levomilnacipran; and 8 were almost never (10.5%) in the green bin: citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, and sertraline. Of the 16 antipsychotics evaluated, they found that 4 were virtually always (>90%) in the green bin: asenapine, lurasidone, paliperidone, and ziprasidone; and 2 were almost never (10.5%) in the green bin: chlorpromazine and thioridazine. What was common among those drugs almost always in the green bin versus those almost never in the green bin were newer versus older marketed drugs and those not dependent versus dependent on oxidative metabolism for their clearance. The authors concluded that the results of this pharmacogenetic testing could be predicted on the basis of knowledge of the pharmacology of the drugs, particularly whether their clearance was dependent on oxidative drug metabolism.
引用
收藏
页码:416 / 419
页数:4
相关论文
共 50 条
  • [31] Providers' Use of Pharmacogenetic Testing to Inform Antidepressant Prescribing: Results of Qualitative Interviews
    Vest, Bonnie M.
    Wray, Laura O.
    Thase, Michael E.
    Brady, Laura A.
    Chapman, Sara R.
    Oslin, David W.
    PSYCHIATRIC SERVICES, 2023, 74 (12) : 1270 - 1276
  • [32] Upfront Imatinib in Pediatric Chronic Myeloid Leukemia Yields Results Comparable to Stem Cell Transplant
    Ganesan, Prasanth
    Sagar, Tenali Gnana
    Kannan, Krishnarathnam
    Rajendranath, Rejiv
    BLOOD, 2011, 118 (21) : 1607 - 1607
  • [33] Pharmacogenetic testing of MDR1 (C3435T) and cytochromes as a tool to increase efficacy of treatment with antipsychotics
    Zhiganova, T.
    Sergeeva, T.
    EUROPEAN PSYCHIATRY, 2019, 56 : S141 - S142
  • [34] Assessment of healthcare professionals' knowledge, attitudes, and perceived challenges of clinical pharmacogenetic testing in Egypt
    Nagy, Mohamed
    Lynch, Meghan
    Kamal, Sherif
    Mohamed, Sarah
    Hadad, Alaa
    Abouelnaga, Sherif
    Aquilante, Christina L.
    PERSONALIZED MEDICINE, 2020, 17 (04) : 251 - 260
  • [35] Knowledge and Attitude of IIUM Final Year Bachelor of Pharmacy Students Regarding Pharmacogenetic Testing
    Zaini, S.
    Akkawi, M. H.
    PUBLIC HEALTH GENOMICS, 2015, 18 : 47 - 47
  • [36] NEW FOUND POWER - MODEL AND MATERIAL TESTING YIELDS RESULTS
    JOHNSON, WF
    ALTERNATIVE SOURCES OF ENERGY, 1984, (67): : 40 - 47
  • [37] Patients' Perceptions of Pharmacogenetic Testing and Access to Their Results: State of the Art in Spain and Systematic Review
    Zubiaur, Pablo
    Prosper-Cuesta, David Nicolas
    Novalbos, Jesus
    Mejia-Abril, Gina
    Navares-Gomez, Marcos
    Villapalos-Garcia, Gonzalo
    Soria-Chacartegui, Paula
    Abad-Santos, Francisco
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
  • [38] Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial
    van der Baan, F. H.
    Knol, M. J.
    Maitland-van der Zee, A. H.
    Regieli, J. J.
    van Iperen, E. P. A.
    Egberts, A. C. G.
    Klungel, O. H.
    Grobbee, D. E.
    Jukema, J. W.
    PHARMACOGENOMICS JOURNAL, 2013, 13 (04): : 318 - 324
  • [39] Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial
    F H van der Baan
    M J Knol
    A H Maitland-van der Zee
    J J Regieli
    E P A van Iperen
    A C G Egberts
    O H Klungel
    D E Grobbee
    J W Jukema
    The Pharmacogenomics Journal, 2013, 13 : 318 - 324
  • [40] Which of Algorithms of Warfarin Dosing Based on Results of Pharmacogenetic Testing is Suitable for Patients in Russia?
    Sychev, D. A.
    Antonov, I. M.
    Kropacheva, E. S.
    Panchenko, E. P.
    KARDIOLOGIYA, 2010, 50 (04) : 35 - 37